deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04617925

A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)

A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

Sponsor: GlaxoSmithKline

Conditions AL Amyloidosis
Interventions Belantamab mafodotin
Updated 12 times since 2020 Last updated: Sep 4, 2025 Started: Feb 26, 2021 Primary completion: Jul 17, 2025 Completion: Jul 17, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on AL Amyloidosis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotNot Yet Recruiting~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshotNot Yet Recruiting~Apr 2021 – ~Sep 2022 · 17 months · monthly snapshotRecruiting~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshotRecruiting~Apr 2023 – ~Feb 2024 · 10 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotRecruiting~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshotActive Not Recruiting~Nov 2024 – ~Oct 2025 · 11 months · monthly snapshotActive Not Recruiting~Oct 2025 – present · 11 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Nov 2024 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 7 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  3. Sep 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  4. Apr 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Stichting European Myeloma Network
Data source: European Myeloma Network B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations